Current neuroscience trends point to a broader competitive shift, as treatment differentiation expands beyond efficacy into delivery, patient populations, complementary mechanisms and evidence strategy.
Coverage Period: August 25 – September 29, 2026
Introduction
The latest neuroscience news and trends point to treatment differentiation expanding beyond efficacy alone. Developers are using new mechanisms, complementary therapies, broader patient populations, convenient administration and alternative evidence strategies to create distinct positions in increasingly complex treatment markets.
This was visible across multiple neurological and neuromuscular diseases. High-efficacy options advanced in multiple sclerosis (MS) and generalized myasthenia gravis (gMG), while spinal muscular atrophy (SMA) gained a muscle-directed treatment designed to complement existing disease-modifying therapy. Huntington’s disease moved closer to a potential gene therapy regulatory decision, while a Phase III setback in myotonic dystrophy type 1 (DM1) highlighted the continuing difficulty of translating promising biology into validated clinical benefit. Together, these developments put clinical differentiation, evidence strategy and treatment positioning at the center of competition.
Companies covered: Roche, Novartis, Kriya Therapeutics, uniQure, Avidity Biosciences, and NexGel
Diseases covered: Multiple sclerosis (MS), Relapsing multiple sclerosis (RMS), Paediatric multiple sclerosis, Spinal muscular atrophy (SMA), Generalized myasthenia gravis (gMG), Huntington’s disease (HD), Myotonic dystrophy type 1 (DM1), Amyotrophic lateral sclerosis (ALS)
Executive Summary
- High-efficacy neurology is expanding across treatment formats and patient populations. Positive Phase III results for oral BTK inhibitor remibrutinib could add another high-efficacy option in relapsing MS, while the CHMP recommendation for Ocrevus in patients aged 10 years and older extends established anti-CD20 treatment into paediatric MS.
- Complementary mechanisms are creating new opportunities in treated rare-disease populations. FDA approval of ISEMBYLD introduces muscle-directed myostatin inhibition on top of SMN2-targeted therapy in SMA, supporting a model in which new therapies address residual impairment rather than replace established disease-modifying treatment.
- Administration and treatment burden are becoming more visible competitive factors. The positive CHMP opinion for once-weekly subcutaneous Klygefa in gMG shows how convenience and patient autonomy can contribute to differentiation alongside clinical efficacy.
- Alternative evidence strategies are testing regulatory boundaries in slowly progressive neurological disease. The US and UK submissions for AMT-130 in Huntington’s disease rely on Phase I/II findings compared with an external natural-history control, making regulatory assessment of the evidence potentially relevant beyond this individual program.
- Endpoint selection remains a major development risk. The Phase III HARBOR miss for del-desiran in DM1 contrasts with the biomarker-intensive design of the early-stage BANYAN ALS trial, highlighting different approaches to establishing biological and clinical evidence in heterogeneous neuromuscular diseases.
Watch the video summary
Strategic Perspective on Current Neuroscience Trends
High-Efficacy Multiple Sclerosis Treatment Expands Across Oral and Paediatric Options
September reinforced a shift in MS from establishing whether high-efficacy treatment is possible toward differentiating how it can be delivered and which patient populations can receive it.
Novartis reported that remibrutinib significantly reduced annualized relapse rates versus teriflunomide across two Phase III relapsing MS studies, with superiority on key MRI endpoints and a favorable reported safety profile. The company plans global regulatory submissions. If approved, an oral BTK inhibitor with competitive efficacy could offer a different treatment proposition within a market that already includes established biologic and oral therapies.
At the same time, Roche’s Ocrevus received a positive CHMP opinion for patients aged 10 years and older with relapsing MS. OPERETTA 2 demonstrated non-inferiority to fingolimod for relapse control and superiority on MRI lesion measures, extending an established adult high-efficacy approach toward an underserved paediatric population.
The market implication is that MS competition may become more segmented by route of administration, age, safety experience and treatment preferences alongside efficacy. Remibrutinib could test demand for high-efficacy oral therapy, while paediatric Ocrevus extends anti-CD20 treatment earlier in the disease course.
Key Uncertainty: The detailed REMODEL dataset, particularly the magnitude and consistency of disability outcomes, will be important for determining remibrutinib’s eventual competitive positioning. For Ocrevus, the final European regulatory decision and subsequent adoption will show how quickly high-efficacy treatment expands within paediatric MS.
Spinal Muscular Atrophy Treatment Expands Through a Complementary Therapy Model
FDA approval of ISEMBYLD in SMA introduces a different competitive model: generating additional functional benefit on top of established disease-modifying therapy rather than attempting to replace it.
ISEMBYLD is approved for patients aged two years and older who are already receiving an SMN2-targeted treatment. Its muscle-directed myostatin mechanism therefore targets a different component of SMA biology. In SAPPHIRE, the approved 10 mg/kg dose produced a 2.2-point HFMSE improvement versus placebo on top of background treatment in the main efficacy population.
This model could matter beyond SMA. As rare-disease markets mature and more patients receive treatments addressing underlying disease mechanisms, residual functional impairment may become a larger development opportunity. Success will depend not only on demonstrating biological activity but also on showing that adding another therapy produces meaningful incremental benefit.
The commercial implications are equally important. Add-on therapies introduce questions around treatment burden, infusion logistics, payer assessment and the value assigned to incremental functional improvement.
Key Uncertainty: Early commercial uptake, payer coverage and real-world treatment patterns will help determine how readily patients and clinicians add muscle-directed therapy to established SMN2 treatment.
Subcutaneous gMG Therapy Raises the Competitive Value of Treatment Convenience
The positive CHMP recommendation for Klygefa in anti-AChR antibody-positive generalized myasthenia gravis highlights another source of differentiation: reducing treatment burden while maintaining clinically meaningful disease control.
The recommendation was based on the Phase III PREVAIL trial, in which Klygefa improved MG-ADL scores versus placebo. The therapy is designed for once-weekly subcutaneous self-administration via autoinjector, potentially differentiating it through convenience as well as its dual-binding nanobody C5-inhibition mechanism.
This matters because treatment delivery can influence positioning as therapeutic choice expands. In markets with multiple effective mechanisms, administration frequency, site of care and patient autonomy may become more important parts of product selection.
For developers, this raises the competitive threshold. Clinical efficacy remains essential, but treatment experience may increasingly determine how therapies are positioned against alternatives targeting the same disease.
Key Uncertainty: European approval and subsequent uptake will provide a clearer test of how strongly self-administration influences treatment selection in gMG when clinicians and patients have access to multiple therapeutic approaches.
AMT-130 Huntington’s Gene Therapy Tests External-Control Regulatory Evidence
uniQure’s AMT-130 BLA submission in Huntington’s disease represents one of September’s most consequential regulatory developments. The accelerated-approval application is supported by three-year Phase I/II results compared with a propensity score-matched external control derived from the Enroll-HD natural-history database. A UK marketing application has also been submitted.
The significance extends beyond AMT-130. Slowly progressive neurological diseases can make conventional development programs lengthy and difficult. Regulatory consideration of evidence incorporating natural-history external controls could therefore influence how other developers design programs where traditional randomized evidence is challenging to generate.
However, submission itself does not establish regulatory acceptance of either the treatment effect or the methodology. uniQure also plans longer-term data, which may provide additional information on durability and disease progression.
Key Uncertainty: Regulatory assessment of the external-control methodology, durability of the observed outcomes and the longer-term dataset will determine how informative this program becomes as a precedent for other rare neurological diseases.
DM1 and ALS Programs Put Endpoint and Biomarker Strategy Under Scrutiny
The Phase III HARBOR study of del-desiran in DM1 provides an important counterpoint to September’s regulatory progress. The study did not meet its primary endpoint of video hand opening time, although Novartis reported evidence of clinical activity in secondary endpoints and exploratory analyses and is evaluating the program’s future development path.
The result highlights a persistent challenge in heterogeneous neuromuscular diseases: biological activity may not translate cleanly through a selected pivotal endpoint. It also illustrates why endpoint validation can be as important to development strategy as the therapeutic platform itself.
Tiziana’s Phase 2a BANYAN trial in ALS takes a different approach at an earlier stage. The study incorporates multiple ALS biomarkers and biological measures, including regulatory T-cell profiling, single-cell RNA sequencing, neurofilament light and TSPO-PET/MRI alongside safety assessment to determine whether intranasal foralumab produces its intended biological effects.
The contrast between the programs highlights the value of connecting mechanism, biomarkers and clinical outcomes before advancing into larger trials.
Key Uncertainty: Novartis’ analysis of the full HARBOR dataset will determine whether del-desiran has a viable development path, while BANYAN must first establish coherent biological and safety signals before the clinical potential of foralumab in ALS can be assessed.
What We Are Watching Next in Neuroscience Drug Development
- Remibrutinib: Detailed REMODEL results, particularly disability outcomes, and the timing of global regulatory submissions.
- AMT-130 update: FDA handling of the accelerated-approval application, the role assigned to external-control evidence and forthcoming longer-term data.
- ISEMBYLD: Early uptake, payer positioning and evidence that the add-on treatment model can gain traction alongside established SMN2 therapies.
- Del-desiran and foralumab: Novartis’ decision following full HARBOR analysis and whether BANYAN produces coherent biomarker evidence supporting further ALS development.
- European market expansion: Final regulatory decisions for paediatric Ocrevus and Klygefa and how quickly positive opinions translate into broader treatment access.
Key Takeaway: What Current Neuroscience Trends Signal for Biopharma
The latest neuroscience trends show that competitive advantage is being defined across more dimensions than efficacy alone. High-efficacy therapies are moving into new formats and patient populations, complementary mechanisms are creating add-on treatment models, and developers are testing evidence strategies designed for diseases where conventional trials can be difficult.
The counterpoint is equally important: the HARBOR result demonstrates that promising biology and platform technology cannot substitute for clinically meaningful and well-aligned endpoints. For neuroscience drug development, the strongest emerging strategic signal is therefore the need to connect therapeutic innovation with credible measurement, workable regulatory evidence and a clearly differentiated role in increasingly complex treatment pathways.
🌐 Explore LucidQuest Strategic Roundups across multiple therapy areas for deeper healthcare and pharma analysis
About LucidQuest
LucidQuest helps organizations anticipate change by identifying emerging signals, market shifts, and strategic opportunities.
Learn more: www.lqventures.com
Contact us at: info@lqventures.com